Apellis Pharmaceuticals Enters Clinical Testing Phase in its Age-Related Macular Degeneration Program
Crestwood, KY – February 10th 2015 – Apellis Pharmaceuticals, Inc. announced that it has begun the Phase I clinical trial of its drug compound APL-2